Abstract Number: PB0930
Meeting: ISTH 2022 Congress
Theme: Venous Thromboembolism » Cancer Associated Thrombosis
Background: Cancer associated thrombosis (CAT) is a common complication of cancer and its management is complicated by an increased risk of recurrence and bleeding in these patients. Bevacizumab is an effective anti-angiogenic therapy but increases the risk of bleeding and potentially the risk of CAT.
Aims: The objective of this study was to evaluate the efficacy and tolerance of anticoagulant therapy in the treatment of CAT occurring on bevacizumab, according to the continuation or discontinuation of bevacizumab.
Methods: This was a retrospective multicenter study. Patients with anticoagulated deep vein thrombosis or pulmonary embolism occurring on bevacizumab between June 2000 and December 2020 were included. The primary end point combined the occurrence of thromboembolic recurrence and the occurrence of clinically significant major or non-major bleeding during the entire follow-up period. Secondary end points were recurrence of thromboembolic events, occurrence of bleeding, occurrence of major bleeding, and overall survival.
Results: Of the 162 patients included, bevacizumab was stopped in 70 patients (stop group) and continued in 92 patients (continuation group). During follow-up, 30% of patients experienced CAT recurrence or major or non-major bleeding in the stop group and 29% in the continuation group. Analysis of survival to first event showed no significant difference between the two groups (p=0.19). The same result was found in the multivariate analysis and taking into account the time of exposure to bevacizumab. There was no difference between the groups in recurrence, bleeding, major bleeding, or overall survival.
Conclusion(s): This study suggests the efficacy and safety of anticoagulant therapy with bevacizumab. However, a larger non-inferiority study would be needed to confirm this result.
To cite this abstract in AMA style:
Mayenga M, Falvo N, MAHÉ I, Jannot A, Gazeau B, Meyer G, Sanchez O, Planquette B. Cancer associated thrombosis on bevacizumab: risk of recurrence and bleeding if bevacizumab is stopped or continued [abstract]. https://abstracts.isth.org/abstract/cancer-associated-thrombosis-on-bevacizumab-risk-of-recurrence-and-bleeding-if-bevacizumab-is-stopped-or-continued/. Accessed March 21, 2024.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/cancer-associated-thrombosis-on-bevacizumab-risk-of-recurrence-and-bleeding-if-bevacizumab-is-stopped-or-continued/